🇺🇸 scopolamine HBr in United States

31 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 31

Most-reported reactions

1. Insomnia — 4 reports (12.9%)
2. Blood Pressure Increased — 3 reports (9.68%)
3. Febrile Neutropenia — 3 reports (9.68%)
4. Memory Impairment — 3 reports (9.68%)
5. Nausea — 3 reports (9.68%)
6. Pre-Existing Condition Improved — 3 reports (9.68%)
7. Therapeutic Response Unexpected — 3 reports (9.68%)
8. Urinary Tract Infection — 3 reports (9.68%)
9. Weight Decreased — 3 reports (9.68%)
10. Weight Increased — 3 reports (9.68%)

Source database →

Frequently asked questions

Is scopolamine HBr approved in United States?

scopolamine HBr does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for scopolamine HBr in United States?

Repurposed Therapeutics, Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.